Lilly Pumps $700M into Boston-Based RNA Therapeutics Facility
Summary: Eli Lilly and Company is investing $700 million to build a state-of-the-art facility in Boston’s seaport as part of plans to…
Summary: Eli Lilly and Company is investing $700 million to build a state-of-the-art facility in Boston’s seaport as part of plans to…
Summary : The FDA approved two vonoprazan-based regimens, one with amoxicillin and clarithromycin (Voquezna Triple Pak) and one with amoxicillin (Voquezna Dual…
Summary : Bristol Myers Squibb and Merck KGaA are diving deeper into the protein degradation pool, with both inking partnerships with Amphista Therapeutics…
Summary : Qelbree (i.e. SPN-812) is a nonstimulant ADHD medication containing a serotonin norepinephrine modulating agent approved by the FDA to treat attention deficit…
Summary : Camzyos (mavacamten), the first FDA-approved cardiac myosin inhibitor that directly addresses the root of obstructive hypertrophic cardiomyopathy, has been authorised…
Summary : Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing…
Summary : ORGOVYX® is the first and only oral and rogend privation therapy for advanced hormone-sensitive prostate cancerin Europe Myovant expects to secure European…